KLHL17 activators belong to a class of chemical compounds that target and modulate the activity of the KLHL17 protein, which is a member of the Kelch-like family characterized by a series of repeats that form a kelch motif. KLHL17, also known as kelch-like protein 17, is implicated in a variety of cellular processes due to its role in protein-protein interactions. These activators are designed to enhance the function of KLHL17, either by increasing its stability, promoting its interaction with other proteins, or facilitating its localization to specific cellular compartments where it exerts its action. The molecular intricacies of KLHL17 activation are complex, as the process may involve conformational changes in the protein structure that enhance its affinity for partner proteins or substrates, or perhaps the prevention of degradation pathways that would otherwise decrease KLHL17 levels.
The development and characterization of KLHL17 activators require a detailed understanding of the protein's structure and the molecular pathways it is involved in. The activators typically work by binding to the KLHL17 protein at specific sites that are critical for its function. These sites could be located in the kelch domain or other functional domains of the protein, which play a role in its ability to interact with other proteins and execute its functions. By binding to these sites, KLHL17 activators can induce conformational changes that either expose interaction sites or stabilize the protein in a configuration that is more conducive to function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
An inhibitor of GSK-3β that can stabilize proteins by preventing their ubiquitination and degradation, which may indirectly increase the levels of KLHL17. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that could lead to the demethylation and subsequent transcription of genes, potentially affecting KLHL17 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that can increase gene expression by altering chromatin structure, possibly leading to enhanced KLHL17 synthesis. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Another GSK-3β inhibitor that can increase protein stability and may enhance the levels or activity of KLHL17. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor used to block the degradation of ubiquitinated proteins, which may stabilize KLHL17. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
An activator of adenylate cyclase which raises intracellular cAMP levels, potentially leading to altered gene expression and increased KLHL17 levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
A histone deacetylase inhibitor which can increase acetylation of histones, leading to a more relaxed chromatin structure and potentially higher expression of KLHL17. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that may influence cytoskeletal organization and could affect cellular processes involving KLHL17. | ||||||